| 1542770-BC-LTD |
1542770-BC-LTD |
92%
|
Pursuant to the terms and conditions of the Second Amendment, on the Effective Date, the Acquiror (i) issued 270 shares of Series B-1 Convertible Preferred Stock to Seller (such shares, the "Seller B… |
| E-F-HUTTON-CO |
E-F-HUTTON-CO |
92%
|
In connection with the Merger, the Acquiror issued to E.F. Hutton & Co. (i) 750 shares of Series B-1 Preferred Stock convertible, subject to Requisite Approval, into 3,024,749 shares of Acquiror Comm… |
| IR-AGENCY |
IR-AGENCY |
92%
|
As consideration for the performance of the Services, the Company paid IR Agency $1.5 million. |
| IR-AGENCY-LLC |
IR-AGENCY-LLC |
92%
|
As consideration for the performance of the services, the Company paid $ 1.25 million to IR Agency. |
| ZHITIAN-ANDY-ZHANG |
ZHITIAN-ANDY-ZHANG |
92%
|
Pursuant to the terms and conditions of the Second Amendment, on the Effective Date, the Acquiror (i) issued 270 shares of Series B-1 Convertible Preferred Stock to Seller (such shares, the "Seller B… |
| 1542770-B-C-LTD |
1542770-B-C-LTD |
90%
|
In exchange for the acquired assets, the Company agreed to pay the Selling Parties (i) a cash payment of $ 3,000,000 at Closing, (ii) a first installment of $ 3,000,000 payable six months after Closi… |
| 1563868-B-C-LTD |
1563868-B-C-LTD |
90%
|
Pursuant to the terms and conditions of the Second Amendment, on the Effective Date, the Acquiror (i) issued 270 shares of Series B-1 Convertible Preferred Stock to Seller (such shares, the "Seller B… |
| ALTO-OPPORTUNITY-MASTER-FUND-SPC-SEGREGATED-MAST |
ALTO-OPPORTUNITY-MASTER-FUND-SPC-SEGREGATED-MAST |
90%
|
Amendment No. 1 to the Amendment Agreement, dated June 4, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC – Segregated… |
| BROWN-UNIVERSITY-LIFESPAN-RHODE-ISLAND-HOSPITAL |
BROWN-UNIVERSITY-LIFESPAN-RHODE-ISLAND-HOSPITAL |
90%
|
Subcontract to Brown University/LifeSpan Rhode Island Hospital. |
| GEORGETOWN-UNIVERSITY |
GEORGETOWN-UNIVERSITY |
90%
|
10.52 License Agreement, dated October 24, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc. and Georgetown University |
| SRO-LLC |
SRO-LLC |
90%
|
10.54 Securities Purchase Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Diagnostics, Inc. and SRO LLC |
| THERADEX-SYSTEMS-INC |
THERADEX-SYSTEMS-INC |
80%
|
the Company received a letter from Theradex Systems, Inc., providing written notice of termination of the master agreement |
